Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

VJOncology were excited to attend the 47th San Antonio Breast Cancer Symposium (SABCS) 2024, bringing you the highly-anticipated trial data and insightful perspectives from leading experts in breast cancer! This international scientific symposium allows for important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer.
View all videos

SABCS 2024

10–13 December 2024 | San Antonio, TX

SABCS 2024

10–13 December 2024 | San Antonio, TX
VJOncology were excited to attend the 47th San Antonio Breast Cancer Symposium (SABCS) 2024, bringing you the highly-anticipated trial data and insightful perspectives from leading experts in breast cancer! This international scientific symposium allows for important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer.
View all videos

Watch all videos from SABCS 2024!

View all
4:07
DECRESCENDO: de-escalating chemotherapy in HER+, HR- early breast cancer
Elisa Agostinetto • 12 Dec 2024
1:57
LITESPARK-029: belzutifan with fulvestrant in ER+/HER2- breast cancer
Bora Lim • 12 Dec 2024
1:36
EUROPA: radiotherapy versus endocrine therapy in low-risk early breast cancer
Icro Meattini • 12 Dec 2024
1:08
COMET: patient-reported outcomes in active monitoring versus GCC for DCIS
Puneet Singh • 13 Dec 2024

Latest news in HER2+ breast cancer!

View all
3:30
PACE: prognostic and predictive biomarkers in ER+/HER2- advanced breast cancer
Guilherme Nader-Marta • 13 Dec 2024
3:21
Insights into mRNA expression in ADC targets in metastatic breast cancer
Kristien Borremans • 12 Dec 2024
1:30
Trials updates at SABCS 2024: EMBER-3 and PATINA
Jason Mouabbi • 13 Dec 2024
0:47
Anthracycline benefit in early HR+/HER2- breast cancer
Nan Chen • 13 Dec 2024

Latest news in TNBC!

View all
0:46
Evaluating the clinical significance of PDX models in breast cancer research
Jonathan Lei • 12 Dec 2024
1:28
Advances in understanding and treating breast cancer brain metastases
Anna Thulin • 13 Dec 2024
1:57
Biomarker-based chemotherapy optimization for TNBC with PDX models
Jonathan Lei • 12 Dec 2024
1:35
Hormone receptor profiles in Syrian patients with breast cancer
Ayla Kouli • 13 Dec 2024

Latest news in HR+ breast cancer!

View all
1:30
Trials updates at SABCS 2024: EMBER-3 and PATINA
Jason Mouabbi • 13 Dec 2024
0:47
Anthracycline benefit in early HR+/HER2- breast cancer
Nan Chen • 13 Dec 2024
1:23
TIME and estrogen deprivation resistance in HR+ breast cancer
Fabiana Napolitano • 13 Dec 2024
3:07
Prognostic value of intrinsic subtypes in HR+/HER2- breast cancer after CDK4/6 inhibitors
Francesco Schettini • 13 Dec 2024

See who we will be interviewing this year!

Sara Tolaney
MD, MPH
Dana Farber Cancer Institute
Icro Meattini
MD
University of Florence
Kevin Kalinsky
MD, MS
Winship Cancer Institute of Emory University
Matteo Lambertini
MD, PhD
IRCCS Ospedale Policlinico San Martino
Komal Jhaveri
MD, FACP
Memorial Sloan Kettering Cancer Center
The content of VJOncology is intended for healthcare professionals